New cancer drug SG2918 enters first human safety trial

NCT ID NCT06167486

First seen Mar 25, 2026 · Last updated May 15, 2026 · Updated 7 times

Summary

This early-stage study tests a new drug called SG2918 in 17 people with advanced cancers that have not responded to standard treatments. The main goal is to check if the drug is safe and tolerable, and to see early signs of whether it can help control the disease. Participants receive the drug and are closely monitored for side effects and how the drug moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400000, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450003, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410031, China

  • Shanghai first maternity and infant hospital

    Shanghai, Shanghai Municipality, 200126, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, 30013, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310005, China

Conditions

Explore the condition pages connected to this study.